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Anti-Alpha-2-Macroglobulin-Like-1 Autoantibodies
Are Detected Frequently and May Be Pathogenic in
Paraneoplastic Pemphigus
Sanae Numata1, Kwesi Teye1, Daisuke Tsuruta1,4, Ryosuke Sogame1, Norito Ishii1, Hiroshi Koga1,
Yohei Natsuaki1, Atsunari Tsuchisaka1, Takahiro Hamada1, Tadashi Karashima1, Takekuni Nakama1,
Minao Furumura1, Chika Ohata1, Tamihiro Kawakami2, Isabelle Schepens3, Luca Borradori3 and
Takashi Hashimoto1
Paraneoplastic pemphigus (PNP) shows autoantibodies mainly to plakin and desmosomal cadherin family
proteins. We have recently identified alpha-2-macroglobulin-like-1 (A2ML1), a broad range protease inhibitor, as a
unique PNP antigen. In this study, we tested a large number of PNP sera by various methods. Forty (69.0%) of 58
PNP sera recognized A2ML1 recombinant protein expressed in COS7 cells by immunofluorescence (IF) and/or
immunoprecipitation (IP)/immunoblotting (IB). IP/IB showed higher sensitivity than IF. In addition, 22 (37.9%) PNP
sera reacted with A2ML1 by IB of cultured normal human keratinocytes (NHKs) under non-reducing conditions.
Statistical analyses using various clinical and immunological data showed that the presence of anti-A2ML1
autoantibodies was associated with early disease onset and absence of ocular lesions. Next, to investigate the
pathogenic role of anti-A2ML1 antibody, we performed additional functional studies. Addition of anti-A2ML1
polyclonal antibody to culture media decreased NHK cell adhesion examined by dissociation assay, and increased
plasmin activity detected by casein zymography, suggesting that anti-A2ML1 antibody may decrease NHK cell
adhesion through plasmin activation by inhibition of A2ML1. This study demonstrates that autoantibodies to
A2ML1 are frequently and specifically detected and may have a pathogenic role in PNP.
Journal of Investigative Dermatology (2013) 133, 1785–1793; doi:10.1038/jid.2013.65; published online 14 March 2013
INTRODUCTION
Paraneoplastic pemphigus (PNP) is an autoimmune multi-
organ syndrome with intractable stomatitis and polymorphous
cutaneous lesions (Anhalt et al., 1990), and underlying
neoplasias are mainly lymphoproliferative tumors (Wolff
et al., 1999; Hsiao et al., 2001; Kimyai-Asadi and Jih, 2001;
Mimouni et al., 2002).
PNP sera recognize various autoantigens by immunopreci-
pitation (IP) or immunoblotting (IB) (Oursler et al., 1992;
Hashimoto et al., 1995). IgG antibodies in PNP sera typically
bind to plakin family proteins, including desmoplakins I and II,
BP230, periplakin (PPL) (Kiyokawa et al., 1998), and
envoplakin (EPL) (Ruhrberg et al., 1996; Kim et al., 1997;
Kiyokawa et al., 1998), as well as desmoglein 3 (Dsg3) and/or
Dsg1 (Hashimoto et al., 1995; Amagai et al., 1998). Finally,
we have recently identified the 170 kDa antigen as alpha-2-
macroglobulin-like-1 (A2ML1) (Schepens et al., 2010). A2ML1
is a broad range protease inhibitor belonging to alpha-2-
macroglobulin family. Northern blot and reverse transcriptase-
PCR studies revealed A2ML1 messenger RNA in epidermal
keratinocytes.
Keratinocyte differentiation was found to associate with
increased expression levels of A2ML1 (Galliano et al., 2006;
Schepens et al., 2010). By immunohistochemistry, A2ML1 was
detected within keratinocytes between the uppermost granular
layers and the cornified cell layers of the epidermis.
Specifically, A2ML1 is secreted into the extracellular space,
and inhibits in vitro various proteases, including chymo-
trypsin, papain, thermolysin, and subtilisin A (Galliano et al.,
2006). In addition, A2ML1, in analogy with alpha-2-macro-
globulin, is thought to have a role in defense mechanisms,
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maintenance of epidermal homeostasis, and regulation of
cytokine and growth factor releases (Galliano et al., 2006).
However, the prevalence of autoantibodies to A2ML1 was
not studied in large series of PNP sera, and clinical and
immunological significance and pathogenic role of anti-
A2ML1 autoantibodies in PNP are still unknown (Schepens
et al., 2010). In this study, we have systematically examined
58 PNP sera by various techniques to search for the presence
of anti-A2ML1 autoantibodies, and performed statistical
analysis between the presence of anti-A2ML1 antibodies and
clinical and immunological characteristics. Furthermore, we
performed dissociation assay and protease assay to investigate
the pathogenic role of anti-A2ML1 antibody.
RESULTS
A2ML1 was expressed in the normal epidermis but not in the rat
bladder
Expression profile of A2ML1 in the skin and rat bladder was
verified by immunofluorescence (IF) using anti-A2ML1 mouse
polyclonal antibody (pAb). A2ML1 was expressed in the
granular layers of the normal human epidermis (Figure 1a),
as described previously (Galliano et al., 2006; Schepens et al.,
2010). In contrast, A2ML1 was not expressed in the rat
bladder, whereas IgG antibodies in PNP serum clearly
reacted with transitional epithelia (Figure 1b).
COS7 cells expressing A2ML1 recombinant protein (RP) were
recognized by PNP sera in IF
We then assessed the reactivity of all 58 PNP sera by IF using
transiently transfected COS7 cells expressing c-Myc-tagged
human A2ML1 RP. Both anti-c-Myc rabbit pAb and anti-
A2ML1 pAb stained the cytoplasm of transfected COS7 cells
in a granular pattern (Figure 2a). The obtained signals showed
perfect colocalization with those by PNP sera, indicating that
the PNP sera recognized A2ML1 (Figure 2a). In the IF study for
all 58 PNP sera, 30 (51.7%) sera recognized A2ML1 RP on
COS7 cells (Figure 2b).
c-Myc-tagged recombinant A2ML1 RP was detected inside of
transfected COS7 cells but not in culture media
Proteins in COS7 cells transfected with A2ML1 complemen-
tary DNA (cDNA) were separated into four different fractions;
i.e., culture medium, washing buffer (cold PBS (phosphate-
buffered saline)) extract, IP buffer extract, and final pellet.
Although protein bands corresponding to the 172 kDa A2ML1
RP (including c-Myc tag) were seen only faintly in IP buffer
extract and pellet by protein staining with amido-black, IB
using anti-c-Myc pAb clearly showed the RPs in IP buffer
extract and pellet but not in culture medium or washing buffer
extract (Figure 3a). Additional experiments confirmed that the
same A2ML1 RP in IP buffer extract was detected by both anti-
A2ML1 pAb and anti-c-Myc pAb (Figure 3b).
IgG anti-A2ML1 autoantibodies were detected in PNP sera by IP
and IB (IP–IB) of COS7 cells transfected with A2ML1 cDNA
By preliminary IB studies of either A2ML1-expressing COS7 cell
extracts or normal human epidermal extracts under standard
reducing condition, none of PNP, pemphigus vulgaris (PV),
pemphigus foliaceus (PF), bullous pemphigoid (BP), or normal
control sera detected A2ML1 proteins (data not shown), con-
firming the results of our previous studies that PNP sera do not
react with A2ML1 in IB under standard reducing conditions.
Then, we examined all 58 PNP sera, diseases control sera,
and normal sera by IP–IB of extracts of A2ML1 RP-expressing
COS7 cells. Proteins immunoprecipitated with sera were
separated on SDS-PAGE and immunoblotted with anti-c-Myc
pAb. In this study, 35 (60.3%) of 58 PNP sera reacted with
c-Myc-tagged A2ML1 RP (Figure 3c). None of the 10 sera each
from PV, PF, and BP patients and 30 normal human sera
reacted with A2ML1 RP (Figure 3c).
PNP sera recognized A2ML1 in differentiated cultures of normal
human keratinocytes (NHKs) by IB under non-reducing condition
To examine whether PNP sera detect disulfide bond–related
conformational epitopes, we performed IB of NHK extracts
A2ML1 pAb
Normal human skin Rat bladder
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Figure 1. Immunofluorescence (IF) for expression of alpha-2-macroglobulin-like-1 (A2ML1) in the human skin and rat bladder. (a) IF of normal human skin
sections. (b) IF of rat bladder sections. Anti-A2ML1 mouse polyclonal antibody (A2ML1 pAb), purified normal mouse IgG, paraneoplastic pemphigus (PNP) serum,
and normal human serum were used. Bar¼ 100mm.
S Numata et al.
Anti-A2ML1 Antibodies in PNP
1786 Journal of Investigative Dermatology (2013), Volume 133
under both reducing and non-reducing conditions for all 58
PNP sera. Twenty-two (37.9%) PNP sera recognized a protein
comigrating with A2ML1 detected by anti-A2ML1 pAb under
non-reducing condition (Figure 3d). None of the 5 PV sera, 5
PF sera, 5 BP sera, and 15 normal human sera showed this
reactivity (Figure 3d). In contrast, under reducing condition,
none of the same set of PNP and control sera recognized the
170 kDa A2ML1 protein band, which was strongly detected by
anti-A2ML1 pAb (Figure 3e).
Statistical comparison of clinical and immunological conditions
between anti-A2ML1 antibody–positive and –negative PNP patients
We statistically analyzed the relationship between the pre-
sence of anti-A2ML1 autoantibodies and various clinical and
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Figure 2. Immunofluorescence (IF) studies of alpha-2-macroglobulin-like-1 (A2ML1) complementary DNA (cDNA)-transfected COS7 cells. (a) IF of COS7
cells expressing c-Myc-tagged A2ML1, triple-stained with a representative paraneoplastic pemphigus (PNP) serum and 40,6-diamidino-2-phenylindole (DAPI), as
well as with either anti-c-Myc pAb or anti-A2ML1 mouse polyclonal antibody (A2ML1 pAb). Bar¼ 20mm. (b) IF of A2ML1-expressing COS7 cells, double-stained
with 58 PNP sera and DAPI. The case numbers are the same as the case numbers in immunoprecipitation and immunoblotting (IP–IB) figure and Supplementary
Table S1 online. PNP2, PNP4, PNP7, PNP8, and PNP9 showed positive reactivity, while PNP1, PNP3, PNP11, and PNP13 were negative. Positive cells are
indicated by arrows. Bar¼100mm.
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immunological findings in PNP (Figure 4 and Table 1).
The 40 PNP sera (69.0%) with positive reactivity in
IP–IB and/or COS7 cell IF were considered as anti-A2ML1
antibody-positive (A2ML1-positive). A2ML1-postive PNP
cases had significantly earlier disease onset than A2ML1-
negative PNP cases (P¼ 0.026) (Figure 4). Interestingly, ocular
mucous membrane lesions occurred less frequently in A2ML1-
postive PNP cases (P¼0.050) (Figure 4). There was no
significant correlation of the presence of anti-A2ML1
antibodies with any other parameters (Figure 4 and Table 1).
In Supplementary Table S1 online, relevant clinical para-
meters and the results for all studies of anti-A2ML1 antibodies
are summarized.
A2ML1 was present in NHK culture medium
As the first step of functional studies of anti-A2ML1 antibody,
we examined the presence of A2ML1 in NHK culture
medium by IB of NHKs at low and high levels of calcium.
No A2ML1 was detected in non-concentrated NHK
culture media (data not shown). In 100 concentrated
culture media, A2ML1 was detected in NHKs cultured at
both low and high calcium levels (Figure 5a). A2ML1 was
also detected in NHK extracts weakly at low calcium and
strongly at high calcium (Figure 5a), as described previously
(Galliano et al., 2006).
Anti-A2ML1 pAb bound to A2ML1 in NHK culture media
To examine whether anti-A2ML1 pAb actually bound to
A2ML1 in culture media, we performed IB of NHK
culture media treated with Protein G agarose. After IP with
Protein G, A2ML1 was detected in NHK culture medium
incubated with normal mouse IgG, but not with anti-A2ML1
pAb (Figure 5b).
Figure 3. Immunoblotting (IB) study of four fractions of COS7 cells,
immunoprecipitation and immunoblotting (IP–IB) of alpha-2-macroglobulin-
like-1 (A2ML1) complementary DNA (cDNA)–transfected COS7 cells for
various sera, and IB of normal human keratinocyte (NHK) extracts under non-
reducing and reducing conditions. (a) Blots of four fractions obtained from
A2ML1 cDNA–transfected COS7 cells, stained with amido-black (left panel),
and processed for IB for anti-c-Myc pAb (right panel). (b) IP buffer extracts of
COS7 cells transfected with or without A2ML1 cDNA were stained with
amido-black, and processed for IB using both anti-c-Myc pAb and anti-A2ML1
mouse polyclonal antibody (A2ML1 pAb). (c) IP buffer extracts of transfected
COS7 cells were immunoprecipitated with the representative paraneoplastic
pemphigus (PNP) sera, disease control sera, and normal sera, as well as anti-c-
Myc pAb, and immunoblotted with anti-c-Myc pAb. The A2ML1 recombinant
protein (RP) was detected by sera of PNP1–PNP10 (lanes 4–13), but not by sera
of PNP11–PNP13 (lanes14–16). In lane 26, IP buffer extract of transfected
COS7 cell was directly stained by IB with anti-c-Myc pAb. The positions of
molecular weight (MW) markers and A2ML1 RP are shown by bars and arrows,
respectively, in the left of each panel. (d) The results of IB under non-reducing
condition. MWs are not shown, because MW markers cannot be used in this
condition. The PNP sera with numbers surrounded by squares, but no control
sera, reacted with the protein band corresponding to A2ML1. Some PNP sera
also reacted with envoplakin (EPL) and periplakin (PPL). (e) IB under reducing
condition. No sera reacted with the 170 kDa A2ML1, while some PNP sera
reacted with EPL or PPL. Positions of EPL, PPL, and A2ML1 are shown in the
left of each panel. BP, bullous pemphigoid; PF, pemphigus foliaceus.
Amido black IB
(kDa) (kDa)
250 250
150 150
100 100
75 75
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2
2 2 2 2 2221111111111
3 4 5 6
1 2 3
EPL
PPL
A2ML1
4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2
2 2 2 2 2221111111111
3 4 5 6
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2
2 2 2 2 2221111111111
3 4 5 6
172 kDa
RP
172 kDa
RP
cDNA
172 kDa
RP
(kDa)
250
150
100
75
(–) (+) (–) (+) (–) (+)
1 2 3 4 5 1
1
2
2
3
3
4
4
5
5 6
(kDa)
250
150
100
75
172 kDa
RP
210 kDa EPL
190 kDa PPL
A2ML1
Pe
lle
t
A2
M
L1
 p
Ab
C-
M
yc
 p
Ab
Am
id
o 
bl
ac
k
Pe
lle
t
IP
 b
u
ffe
r
IP
 b
u
ffe
r
W
a
sh
in
g 
bu
ffe
r
W
a
sh
in
g 
bu
ffe
r
M
ed
iu
m
M
ed
iu
m
M
W
 m
ar
ke
rs
M
W
 m
ar
ke
rs
Ce
ll e
xt
ra
ct
N
or
m
a
l3
N
or
m
a
l2
N
or
m
a
l2
N
or
m
a
l3
N
or
m
a
l3
N
or
m
a
l2
N
or
m
a
l1
N
or
m
a
l1
N
or
m
a
l1
BP
2
BP
2
BP
2
BP
1
BP
1
BP
1
PF
2
PF
2
PF
2
PF
1
PF
1
PF
1
PV
2
PV
2
PV
2
PV
1
PV
1
PV
1
PN
P1
3
PN
P1
3
PN
P1
3
Non-reducing IB
Reducing IB
PN
P1
2
PN
P1
2
PN
P1
2
PN
P1
1
PN
P1
1
PN
P1
1
PN
P1
0
PN
P1
0
PN
P1
0
PN
P9
PN
P9
PN
P9
PN
P8
PN
P8
PN
P8
PN
P7
PN
P7
PN
P7
PN
P6
PN
P6
PN
P6
PN
P5
PN
P5
PN
P5
PN
P4
PN
P4
PN
P4
PN
P3
PN
P3
PN
P3
PN
P2
PN
P2
PN
P2
PN
P1
PN
P1
PN
P1
C-
M
yc
 p
Ab
PP
L 
m
Ab
PP
L 
m
Ab
EP
L 
pA
b
EP
L 
pA
b
M
ou
se
 Ig
G
M
ou
se
 Ig
G
A2
M
L1
 p
A
A2
M
L1
 p
Ab
M
W
 m
ar
ke
r
1s
t A
b(–
)
S Numata et al.
Anti-A2ML1 Antibodies in PNP
1788 Journal of Investigative Dermatology (2013), Volume 133
Anti-A2ML1 pAb reduced cell–cell adhesion of cultured NHKs
We determined the effect of anti-A2ML-1 pAb on NHK cell
adhesion by dissociation assay. Remarkable increase in
fragmentation of culture sheets of NHKs was induced by
incubation with anti-A2ML1 pAb, but not with anti-PPL mAb
or normal mouse IgG (Figure 5c).
Anti-A2ML1 pAb increased plasmin activity in NHK culture
medium
Although we tried to detect protease activity using colori-
metric protease assay kit, the sensitivity is too low to detect the
protease activity (data not shown). Then, we examined
protease activity in culture medium by casein gel zymogra-
phy. Increased serine protease activity, corresponding to
plasmin, was detected in culture medium of NHK incubated
with anti-A2ML1 pAb, but not with anti-PPL mAb, normal
mouse IgG, or no antibody addition (Figure 5d). No activity of
other proteases was detected.
DISCUSSION
In this study, double-staining IF of COS7 cells transiently
transfected with human A2ML1 cDNA confirmed the specific
reactivity of PNP sera with A2ML1. By this IF, 30 (51.7%) of
58 PNP sera reacted with A2ML1-expressing COS7 cells. By
IP–IB using lysates of A2ML1-expressing COS7 cells, A2ML1
was detected by 35 (60.3%) of 58 PNP sera, but not by any
disease and normal control sera. Precisely, the IF showed
negative results in 10 IP–IB–positive sera, and conversely
positive results in 5 IP–IB–negative sera. Thus, 40 (69.0%) of
58 PNP sera recognized A2ML1, when the results in IP–IB and
IF studies of A2ML1-expressing COS7 cells were combined.
This frequency of anti-A2ML1 antibodies is higher than the
positive reactivity in 10 (50%) of 20 PNP sera in our previous
IP–IB study (Schepens et al., 2010). The detection rate of about
70% is similar to those obtained by conventional IP with
radiolabeled-cultured NHK extracts in previous case reports
and smaller population systematic studies (Nishibori et al.,
1995; Izaki et al., 1996; Mahler et al., 1998; Williams et al.,
2000; Inaoki et al., 2001; Fujimoto et al., 2002; Mimouni
et al., 2002; Martinez De Pablo et al., 2005; Marzano et al.,
2005; Santi et al., 2005; Lee et al., 2006).
Thus, by using a larger series of unselected PNP sera, this
study unequivocally and independently confirms that A2ML1 is
one of the major PNP antigens. Although the sensitivity of IF of
A2ML1-expressing COS7 cells was slightly lower than that of
IP–IB, the easier IF may become a useful method to detect anti-
A2ML1 autoantibodies after adequate technical improvements.
Table 1. Clinical and immunological features in 58
PNP cases, differences between anti-A2ML1-antibody–
positive and –negative PNP cases, and statistical
analyses
Parameters
(n¼ cases with description)
A2ML1
positive
A2ML1
negative Total
Gender (n¼53)
Females 24/36 (66.7%) 11/17 (64.7%) 35/53
Males 12/36 (33.3%) 6/17 (35.3%) 18/53
Cutaneous lesions
Trunk (n¼48) 21/33 (63.6%) 10/15 (66.7%) 31/48
Extremities (n¼49) 18/33 (54.5%) 10/16 (62.5%) 28/49
Bronchiolitis obliterans (n¼58) 7/40 (17.5%) 3/18 (22.2%) 10/58
Castleman’s disease (n¼58) 6/40 (15.0%) 2/18 (11.1%) 8/58
Dsg1, indices (n¼ 58) cutoff
index: 420
26.52±38.78 11.86±21.99 21.96±34.93
Dsg3, indices (n¼ 58) cutoff
index: 420
86.14±76.47 75.95±70.70 82.97±74.26
Human skin indirect IF (n¼ 58) 30/40 (75.0%) 14/18 (77.8%) 44/58
Rat bladder indirect IF (n¼58) 29/40 (72.5%) 11/18 (61.1%) 40/58
Acantholysis (n¼43) 17/27 (63.0%) 6/16 (37.5%) 23/43
Necrotic cells (n¼ 43) 12/27 (44.4%) 4/16 (25.0%) 16/43
Liquefaction degeneration
(n¼43)
4/27 (14.8%) 3/16 (18.8%) 7/43
Good response to therapies
(n¼48)
16/32 (50.0%) 8/16 (50.0%) 24/48
Outcome (n¼ 43)
Alive 11/30 (36.7%) 3/13 (23.1%) 14/43
Dead 19/30 (63.3%) 10/13 (76.9%) 29/43
Abbreviations: A2ML1, alpha-2-macroglobulin-like-1; Dsg, desmoglein;
IF, immunofluorescence; PNP, paraneoplastic pemphigus.
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Figure 4. Influence of the presence of anti-alpha-2-macroglobulin-like-1 (A2ML1) antibodies on age at onset of paraneoplastic pemphigus (PNP) and the
appearance of various mucosal lesions. Statistically significant differences were seen in age at disease onset and ocular mucosal lesion, but not in oral, nasal, or
genital mucosal lesions. *P¼0.05 (after Bonferroni adjustment).
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The results in our previous study suggested that intramole-
cular disulfide bonds within A2ML1 molecule are important
for conformational epitopes for autoantibodies in PNP sera
(Schepens et al., 2010). This assumption was further confirmed
by the results in the present study that 22 (37.9%) PNP sera
reacted with A2ML1 in IB of NHKs under non-reducing, but
not reducing condition. To the best of our knowledge, A2ML1
is the antigen, which has such unique epitopes that have not
been reported previously.
However, the positive rate in non-reducing IB of NHK
extracts was much lower than that in IP–IB using A2ML1-
expressing COS7 cells. Noteworthy, all PNP sera with positive
A2ML1 reactivity in non-reducing IB were also positive in IP–
IB, whereas none of IP–IB–negative sera showed positive
reactivity by non-reducing IB (Supplementary Table S1
online), concluding that IP–IB using A2ML1 RP is more
sensitive than non-reducing IB of NHK extracts.
In the second part of this study, we presented the evidence
of the pathogenic role of anti-A2ML1 antibodies in PNP by
functional studies, which to our knowledge is previously
unreported. We first confirmed the presence of A2ML1 in
NHK culture media by IB of concentrated samples. Then, we
also confirmed actual binding of anti-A2ML1 pAb by IB of
culture media immunoprecipitated with protein G agarose.
NHKs incubated with A2ML1 pAb showed decreased cell
adhesion by dissociation assay, and increased activity of
plasmin was detected by casein zymography. The results of
these functional studies suggested that anti-A2ML1 pAb
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Figure 5. Anti-alpha-2-macroglobulin-like-1 (A2ML1) polyclonal Ab (pAb) caused cell–cell dissociation and plasmin activation in cultured normal human
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precipitated with protein G. Although the reactivity was weak, A2ML1 disappeared in culture medium incubated with anti-A2ML1 pAb after precipitation with
protein G agarose (lane 5). The position of A2ML1 RP is shown by arrows in both sides. Extracts of COS7 cells with or without transfection of A2ML1
complementary DNA (cDNA) were used as positive and negative controls, respectively, in both panels (a) and (b). The positions of molecular weight (MW)
markers and a nonspecific band are indicated by bars and asterisks (*), respectively, in the left of both panels (a) and (b). (c) Anti-A2ML1 pAb decreased cell–cell
adhesion of NHKs. Upper panel shows culture dishes after the process of dissociation assay, and lower panel shows numbers of fragments by histograms, in which
each bar corresponds to the dish in the upper panel. NHKs were cultured with anti-A2ML1 pAb, anti-periplakin (PPL) mAb, or normal mouse IgG at a
concentration of 1mg ml 1, or without antibody (Ab( )), for one day after calcium shift. After treatment with dispase II, detached cell sheets were pipetted and
fragments were counted. (d) Anti-A2ML1 pAb increased plasmin activity. Casein zymography was performed using culture media of NHKs cultured with anti-
A2ML1 pAb, anti-PPL mAb, or normal mouse IgG at a concentration of 1mg ml 1, or without antibody (Ab( )), for one day after calcium shift. The arrows in the
left indicate the position of the 91 kDa plasmin and the 23 kDa trypsin.
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decreased NHK cell adhesion through plasmin activation by
inhibition of A2ML1.
Relationship between proteases and acantholysis was pre-
viously described (Morioka et al., 1981), and plasmin and
plasminogen activator (PA) were reported to be involved in the
pathogenesis of pemphigus (Hashimoto et al., 1983; Seishima
et al., 1997). However, this hypothesis was later negated by a
study using PA-knockout mice (Mahoney et al., 1999).
Plasmin activation is controlled by at least two different
systems, i.e., inhibition of processing from plasminogen to
plasmin by PA inhibitor and direct inhibition of plasmin by
anti-plasmin and alpha-2-macroglobulin family inhibitors,
including A2ML1. In addition, A2ML1 may inhibit kallikrein,
which also processes from plasminogen to plasmin, although
kallikrein activation was not found in our study. We suggest
that A2ML1 has strong anti-plasmin activity and anti-A2ML1
autoantibodies may have a role in PNP lesions, probably
through decrease in cell adhesion. However, new approaches
using anti-A2ML1 autoantibodies in PNP sera are needed to
unravel this hypothesis.
In the preliminary IF studies using anti-A2ML1 pAb, A2ML1
was confirmed to be present in uppermost layers of the normal
human epidermis. By IF of rat bladder, which is one of the
diagnostic criteria for PNP, although PNP sera clearly reacted
with transitional epithelia, no positive reactivity was found by
anti-A2ML1 pAb, indicating that A2ML1 is not responsible for
the positive reactivity with rat bladder by PNP sera.
As PNP sera react with multiple antigens, their expression
patterns in various tissues should be important to speculate the
pathogenicity of each antigen. Expressed sequence tags (ESTs)
profile for A2ML1 (Hs.620532, NCBI Unigene, EST profile
viewer) suggests high A2ML1 transcript levels in the esopha-
gus, mouth, pharynx, intestine, and muscle. At protein level,
A2ML1 is also expressed in non-epithelial tissues, including
thymus and testis. Therefore, future studies of the precise
expression of A2ML1 in various tissues should be required to
understand the role of anti-A2ML1 antibodies in the develop-
ment of extra-cutaneous lesions.
In this study, the relationship of the presence of anti-A2ML1
antibodies with various clinical and immunological findings in
PNP patients was also statistically examined. In our analyses,
the presence of anti-A2ML1 autoantibodies was more fre-
quently associated with early onset (Po0.05) and absence of
ocular lesion (P¼ 0.05), while no significant difference was
found in any other parameters, including associated malig-
nancies and bronchiolitis obliterans.
In previous IP studies, antibodies to the 170 kDa antigen
appeared to be detected in young PNP patients (Williams
et al., 2000; Inaoki et al., 2001; Fujimoto et al., 2002;
Mimouni et al., 2002; Niimi et al., 2010), which is in line
with our results. The reason why the presence of anti-A2ML1
antibodies correlates with absence of ocular involvement is
unknown, because the expression of A2ML1 in conjunctivae
has not been studied.
In conclusion, the pathogenic role of anti-A2ML1 antibodies
is still unclear. Anti-A2ML1 antibodies are already detectable
in the initial stage of disease (Reich et al., 1999; Borradori
et al., 2001; Heizmann et al., 2001; Schepens et al., 2010),
and preferentially react with the N-terminal domain of A2ML1
where target proteases bind (Schepens et al., 2010). These
findings raise the possibility that anti-A2ML1 autoantibodies
are involved in the development of PNP lesions, through
various effects, including inhibition of keratinocyte cell
adhesion by activating plasmin, which was suggested in this
study.
MATERIALS AND METHODS
All studies followed the guidelines of the Medical Ethics Committees
of Kurume University School of Medicine, and were conducted
according to the Declaration of Helsinki Principles. Written informed
consents were obtained from all patients and the controls.
Patients and antibodies
Serum samples were obtained from 58 patients with PNP, none of
which were used in our previous study (Schepens et al., 2010). The
diagnosis of PNP was made by the characteristic clinical and
histopathological features, direct IF, indirect IF of normal human
skin sections and rat bladder sections, enzyme-linked immunosorbent
assays of Dsg1 and Dsg3, and recognition of autoantibodies against
the EPL and PPL by IB of normal human epidermal extracts. All
clinical data were collected from clinical chart of each patient, which
are shown in Figure 4, Table 1, and Supplementary Table S1 online.
All sera were taken at the time before therapy or on the incipient stage
of PNP. Age at onset ranged 11–80 years (average, 57.4 years).
Disease control sera were obtained from 10 PV, 10 PF, and 10 BP
patients, and normal control sera were obtained from 30 healthy
volunteers. See Supplementary Materials and Methods for details for
antibodies used in this study.
Indirect IF of normal human skin and rat bladder sections for
A2ML1 protein expression
See Supplementary Materials and Methods for technical details.
IF of A2ML1 cDNA-transfected COS7 cells
The cDNA coding entire human A2ML1 was cloned into pcDNA3
eukaryotic expression vector (Invitrogen, Palo Alto, CA) with c-Myc
tagged in carboxy-terminus, as described previously (Ruhrberg et al.,
1996; Schepens et al., 2010). A2ML1-harboring plasmids were
transfected into COS7 cells using Lipofectamine (Invitrogen). After
48 hours, the cells were fixed with cold 100% methanol and blocked
with 1% BSA/PBS. Cells were double-stained with 1:20 diluted
patient serum, together with either 1:100 diluted anti-c-Myc pAb or
1:50 diluted anti-A2ML1 pAb. Then, the cells were incubated with
appropriate secondary antibodies (1:100 diluted FITC-conjugated
anti-human IgG, 1:1,000 diluted Texas Red-conjugated anti-rabbit
IgG, or 1:1,000 diluted Alexa Fluor 568-conjugaed anti-mouse IgG)
and 40,6-diamidino-2-phenylindole (Nacalai, Kyoto, Japan).
IB of normal human epidermal extracts and transfected COS7
cell extracts
See Supplementary Materials and Methods for technical details
(Hashimoto et al., 1990).
Preparation of fractions of A2ML1 protein
Forty eight hours after transfection with A2ML1 construct, the culture
medium was harvested. After washing the cells with cold PBS, COS7
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cells were scraped in washing buffer (cold PBS) and centrifuged. After
supernatant was stored, PBS containing 1% protease inhibitor cocktail
(PIC, Sigma-Aldrich, St Louis, MO) and 1% polyoxyethylene-9-
octylphenyl ether (NP40, Sigma-Aldrich) (IP buffer) was added to
pellet, mixed gently, and incubated for 20 minutes on ice. After
centrifugation, both supernatant and pellet resuspended with IP buffer
were stored. All the four materials were separated by SDS-PAGE on
5–20% gel (ATTO, Tokyo, Japan) and transferred onto nitrocellulose
membrane by semi-dry transfer method using iBlot (Invitrogen).
Membrane was blocked with 3% skim milk for 1 hour at room
temperature and incubated over night at 4 1C with 1:100 diluted anti-
c-Myc pAb or 1:100 diluted anti-A2ML1 pAb, washed, and probed
with 1:100 diluted horseradish peroxidase (HRP)-conjugated anti-
rabbit IgG or 1:2,000 diluted alkaline phosphatase (AP)-conjugated
anti-mouse IgG. Protein bands were visualized using AP and HRP
detection systems.
IP–IB of A2ML1-transfected COS7 cell extracts
IP–IB was performed with transfected COS7 cell extracts as substrate
for PNP, PV, PF, BP, and normal control sera. In this study, A2ML1
immunoprecipitated with these sera was detected by IB using anti-c-
Myc pAb. IP–IB for eukaryotic recombinant A2ML1 protein was
performed as described previously (Ruhrberg et al., 1996; Schepens
et al., 2010). From preliminary IB results, cell extracts in IP buffer
were used for IP–IB. For preclearance, cell extracts were incubated
with prewashed protein A agarose (Bio-Rad Laboratories, Hercules,
CA) in IP buffer for 30 minutes at 4 1C. After centrifugation, patient
serum or anti-c-Myc pAb (positive control) was added to supernatant
and incubated with rotation overnight at 4 1C. Then, prewashed
protein A agarose was added and incubated for 3 minutes at 4 1C.
After centrifugation, the sepharose were washed with wash buffer
(PBS containing PIC) with rotation for 3 minutes at 4 1C. Proteins
bound to the protein A agarose were eluted by boiling in SDS sample
buffer and processed for IB using 1:100 diluted anti-c-Myc pAb as
described above, except that protein-A/G–HRP conjugate (Pierce,
Rockford, IL) diluted 1:5,000 was used.
IB of NHK extracts under reducing and non-reducing conditions
See Supplementary Materials and Methods for technical details.
Statistical analysis
Differences among qualitative results were compared using the w2 test
and Bonferroni adjustment. Differences among quantitative para-
meters between groups were assessed using the Mann–Whitney test.
All data are expressed as means±SD. All analyses were performed
using SPSS (SPSS, Chicago, IL).
Detection of A2ML1 protein in cultured NHKs
A2ML1 expression in cultured NHKs was examined by IB. NHKs
were cultured in EpiLife medium (Invitrogen) with NHK growth
supplement (Invitrogen). After NHKs were reaching confluency,
medium was changed to the medium containing 1.2 mM calcium
without growth factor and phenol red. We harvested both culture
media and cell extracts of NHKs in low calcium (at day 1) and in high
calcium (at days 1–5). Culture media were concentrated 100 using
Amicon Ultra-0.5–30K (Millipore, Billerica, MA), and cell extracts
were prepared by suspending the NHKs in 1 SDS sample buffer.
IB for A2ML1 was performed as described above.
IB of protein G immunoprecipitated NHK culture media to
confirm binding of anti-A2ML1 pAb to A2ML1
After NHKs were cultured as described above, antibodies were added
to the concentration of 1mg ml 1 and incubated at 37 1C for 24 hours.
Protein G agarose (Millipore) and binding buffer (20 mM NaPO4) were
added to NHK culture media, and incubated for 30 minutes at 4 1C.
After centrifugation, the supernatant was concentrated as above. IB
for A2ML1 was performed by the same method described above.
Dissociation assay
Dissociation assay was performed as described previously (Ishii et al.,
2005; Saleh et al., 2012). NHKs were cultured as described above.
After washing with PBS with calcium and magnesium (PBS (þ )), the
cells were incubated with 2.4 U ml 1 dispase II (Roche Diagnostics,
Mannheim, Germany). Released monolayer was washed with PBS
(þ ) and pipetted five times in 1 ml PBS ( ) using 1 ml pipette. The
cells were fixed for 10 minutes with 5% formaldehyde. Twenty
microliter of 0.02% crystal violet was added and incubated
overnight to stain completely. Three pictures were taken and
number of fragments was counted manually.
Protease assays
Protease assays using Pierce Colorimetric Protease Assay Kit (Thermo,
Rockford, IL) and Serine-Protease detection zymo-electrophoresis Kit
(Cosmo Bio, Tokyo, Japan) were performed according to the instruc-
tion from manufacturers. Culture medium was prepared and con-
centrated as above. In zymography, areas of caseinolytic activity
appeared as clear zones against a dark blue background. Plasmin and
trypsin (0.5 ng each) were also loaded as controls.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We gratefully appreciate the secretarial work of Ms Hanako Nakagawa, Ms
Mihoko Ikeda, and Ms. Sachika Notomi. We thank the patients for their
participation. This study was supported by Grants-in-Aid for Scientific Research
(nos. 20390308, 20591331, 21659271, 23591634, 23791298, 23791299,
23791300, 23791301, 24659534, 24591672, 24591640, and 24791185), and
Supported Program for the Strategic Research Foundation at Private Univer-
sities from the Ministry of Education, Culture, Sports, Science and Technology;
and by ‘‘Research on Measures for Intractable Diseases’’ Project: matching
fund subsidy (H23-028 to K. Iwatsuki, and H24-038 to T. Hashimoto) from the
Ministry of Health, Labor and Welfare. The study was also supported by grants
from the Kaibara Morikazu Medical Science Promotion Foundation, Ishibashi
Foundation, Kanae Foundation for the Promotion of Medical Science, Takeda
Science Foundation, Chuo Mitsui Trust and Banking Company, Limited, and
Nakatomi Foundation.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Amagai M, Nishikawa T, Nousari HC et al. (1998) Antibodies against
desmoglein 3 (pemphigus vulgaris antigen) are present in sera from
patients with paraneoplastic pemphigus and cause acantholysis in vivo in
neonatal mice. J Clin Invest 102:775–82
Anhalt GJ, Kim SC, Stanley JR et al. (1990) Paraneoplastic pemphigus.
An autoimmune mucocutaneous disease associated with neoplasia.
N Engl J Med 323:1729–35
Borradori L, Lombardi T, Samson J et al. (2001) Anti-CD20 monoclonal
antibody (rituximab) for refractory erosive stomatitis secondary to
S Numata et al.
Anti-A2ML1 Antibodies in PNP
1792 Journal of Investigative Dermatology (2013), Volume 133
CD20(þ ) follicular lymphoma-associated paraneoplastic pemphigus.
Arch Dermatol 137:269–72
Fujimoto W, Kanehiro A, Kuwamoto-Hara K et al. (2002) Paraneoplastic
pemphigus associated with Castleman’s disease and asymptomatic
bronchiolitis obliterans. Eur J Dermatol 12:355–9
Galliano MF, Toulza E, Gallinaro H et al. (2006) A novel protease inhibitor of
the macroglobulin family expressed in the human epidermis. J Biol Chem
281:5780–9
Hashimoto K, Shafran KM, Webber PS et al. (1983) Anti-cell surface
pemphigus autoantibody stimulates plasminogen activator activity of
human epidermal cells. A mechanism for the loss of epidermal cohesion
and blister formation. J Exp Med 157:259–72
Hashimoto T, Amagai M, Watanabe K et al. (1995) Characterization of
paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest
Dermatol 104:829–34
Hashimoto T, Ogawa MM, Konohana A et al. (1990) Detection of pemphigus
vulgaris and pemphigus foliaceus antigens by immunoblot analysis using
different antigen sources. J Invest Dermatol 94:327–31
Heizmann M, Itin P, Wernli M et al. (2001) Successful treatment of
paraneoplastic pemphigus in follicular NHL with rituximab: report of a
case and review of treatment for paraneoplastic pemphigus in NHL and
CLL. Am J Hematol 66:142–4
Hsiao CJ, Hsu MM, Lee JY et al. (2001) Paraneoplastic pemphigus in
association with a retroperitoneal Castleman’s disease presenting with a
lichen planus pemphigoides-like eruption. A case report and review of
literature. Br J Dermatol 144:372–6
Inaoki M, Kodera M, Fujimoto A et al. (2001) Paraneoplastic pemphigus
without antidesmoglein 3 or antidesmoglein 1 autoantibodies. Br J
Dermatol 144:610–3
Ishii K, Harada R, Matsuo I et al. (2005) In vitro keratinocyte dissociation assay
for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibo-
dies in pemphigus vulgaris. J Invest Dermatol 124:939–46
Izaki S, Yoshizawa Y, Hashimoto T et al. (1996) Paraneoplastic pemphigus:
report of a case. J Dermatol 23:397–404
Kim SC, Kwon YD, Lee IJ et al. (1997) cDNA cloning of the 210-kDa
paraneoplastic pemphigus antigen reveals that envoplakin is a component
of the antigen complex. J Invest Dermatol 109:365–9
Kimyai-Asadi A, Jih MH (2001) Paraneoplastic pemphigus. Int J Dermatol
40:367–72
Kiyokawa C, Ruhrberg C, Nie Z et al. (1998) Envoplakin and periplakin are
components of the paraneoplastic pemphigus antigen complex. J Invest
Dermatol 111:1236–8
Lee JSS, Pei Lin NgP, Tao M et al. (2006) Paraneoplastic pemphigus resembling
linear IgA bullous dermatosis. Int J Dermatol 45:1093–5
Mahler V, Antoni C, Anhalt GJ et al. (1998) Graft-versus-host-like mucocuta-
neous eruptions with serological features of paraneoplastic pemphigus
and systemic lupus erythematosus in a patient with non-Hodgkin’s
lymphoma. Dermatology 197:78–83
Mahoney MG, Wang ZH, Stanley JR (1999) Pemphigus vulgaris and pemphi-
gus foliaceus antibodies are pathogenic in plasminogen activator knock-
out mice. J Invest Dermatol 113:22–5
Martinez De Pablo MI, Iranzo P, Mascaro JM et al. (2005) Paraneoplastic
pemphigus associated with non-Hodgkin B-cell lymphoma and good
response to prednisone. Acta Derm Venereol 85:233–5
Marzano AV, Vezzoli P, Mariotti F et al. (2005) Paraneoplastic pemphigus
associated with follicular dendritic cell sarcoma and Castleman disease.
Br J Dermatol 153:214–5
Mimouni D, Anhalt GJ, Lazarova Z et al. (2002) Paraneoplastic pemphigus in
children and adolescents. Br J Dermatol 147:725–32
Morioka S, Naito K, Ogawa H (1981) The pathogenic role of pemphigus
antibodies and proteinase in epidermal acantholysis. J Invest Dermatol
76:337–41
Niimi Y, Ohyama B, Di Zenzo G et al. (2010) Paraneoplastic pemphigus
presenting as mild cutaneous features of pemphigus foliaceus and
lichenoid stomatitis with antidesmoglein 1 antibodies. Dermatol Res
Pract 2010, pii931340
Nishibori Y, Hashimoto T, Ishiko A et al. (1995) Paraneoplastic pemphigus: the
first case report from Japan. Dermatology 191:39–42
Oursler JR, Labib RS, Ariss-Abdo L et al. (1992) Human autoantibodies
against desmoplakins in paraneoplastic pemphigus. J Clin Invest 89:
1775–82
Reich K, Brinck U, Letschert M et al. (1999) Graft-versus-host disease-like
immunophenotype and apoptotic keratinocyte death in paraneoplastic
pemphigus. Br J Dermatol 141:739–46
Ruhrberg C, Hajibagheri MA, Simon M et al. (1996) Envoplakin, a novel
precursor of the cornified envelope that has homology to desmoplakin.
J Cell Biol 134:715–29
Saleh MA, Ishii K, Yamagami J et al. (2012) Pathogenic anti-desmoglein 3
mAbs cloned from a paraneoplastic pemphigus patient by phage display.
J Invest Dermatol 132:1141–8
Santi CG, Flores RS, Medina MM et al. (2005) Paraneoplastic pemphigus
associated with pelvic inflammatory fibrosarcoma: a case report.
J Dermatol 32:1014–20
Schepens I, Jaunin F, Begre N et al. (2010) The protease inhibitor
alpha-2-macroglobuline-like-1 is the p170 antigen recognized
by paraneoplastic pemphigus autoantibodies in human. PLoS ONE
5:e12250
Seishima M, Satoh S, Nojiri M et al. (1997) Pemphigus IgG induces expression
of urokinase plasminogen activator receptor on the cell surface of cultured
keratinocytes. J Invest Dermatol 109:650–5
Williams JV, Marks JG Jr, Billingsley EM (2000) Use of mycophenolate
mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol
142:506–8
Wolff H, Kunte C, Messer G et al. (1999) Paraneoplastic pemphigus with fatal
pulmonary involvement in a woman with a mesenteric Castleman
tumour. Br J Dermatol 140:313–6
S Numata et al.
Anti-A2ML1 Antibodies in PNP
www.jidonline.org 1793
